{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:15:12Z","timestamp":1761718512772,"version":"3.41.0"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:p>Aiming to identify new antipsychotic lead-compounds, our group has been working on the design and synthesis of new<jats:italic toggle=\"yes\">N<\/jats:italic>-phenylpiperazine derivatives. Here, we characterized LASSBio-1422 as a pharmacological prototype of this chemical series. Adult male Wistar rats and CF1 mice were used for in-vitro and in-vivo assays, respectively. LASSBio-1422 [1 and 5\u2009mg\/kg, postoperatively (p.o.)] inhibited apomorphine-induced climbing as well as ketamine-induced hyperlocomotion (1 and 5\u2009mg\/kg, p.o.), animal models predictive of efficacy on positive symptoms. Furthermore, LASSBio-1422 (5\u2009mg\/kg, p.o.) prevented the prepulse impairment induced by apomorphine, (\u00b1)-2,5-dimethoxy-4-iodoamphetamine, and ketamine, as well as the memory impairment induced by ketamine in the novel object-recognition task at the acquisition, consolidation, and retrieval phases of memory formation. Potential extrapyramidal side-effects and sedation were assessed by catatonia, rota-rod, locomotion, and barbiturate sleeping time, and LASSBio-1422 (15\u2009mg\/kg, p.o.) did not affect any of the parameters observed. Binding assays showed that LASSBio-1422 has a binding profile different from the known atypical antipsychotic drugs: it does not bind to AMPA, kainate,<jats:italic toggle=\"yes\">N<\/jats:italic>-methyl-<jats:sc>d<\/jats:sc>-aspartate, glicine, and mGluR<jats:sub>2<\/jats:sub>receptors and has low or negligible affinity for D<jats:sub>1<\/jats:sub>, D<jats:sub>2<\/jats:sub>, and 5-HT<jats:sub>2A<\/jats:sub>\/C receptors, but high affinity for D4 receptors (<jats:italic toggle=\"yes\">K<\/jats:italic><jats:sub>i<\/jats:sub>=0.076\u2009\u00b5mol\/l) and, to a lesser extent, for 5-HT<jats:sub>1A<\/jats:sub>receptors (<jats:italic toggle=\"yes\">K<\/jats:italic><jats:sub>i<\/jats:sub>=0.493\u2009\u00b5mol\/l). The antagonist action of LASSBio-1422 at D<jats:sub>4<\/jats:sub>receptors was assessed through the classical GTP-shift assay. In conclusion, LASSBio-1422 is effective in rodent models of positive and cognitive symptoms of schizophrenia and its ability to bind to D<jats:sub>4<\/jats:sub>and 5-HT<jats:sub>1A<\/jats:sub>receptors may at least in part explain its effects in these animal models.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000267","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T10:10:43Z","timestamp":1476439843000},"page":"48-62","source":"Crossref","is-referenced-by-count":10,"title":["LASSBio-1422: a new molecular scaffold with efficacy in animal models of schizophrenia and disorders of attention and cognition"],"prefix":"10.1097","volume":"28","author":[{"given":"Andresa H.","family":"Betti","sequence":"first","affiliation":[{"name":"Department of Raw Material Production, Post Graduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Porto Alegre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila B.","family":"Antonio","sequence":"additional","affiliation":[{"name":"Department of Raw Material Production, Post Graduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Porto Alegre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thais E.T.","family":"Pompeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaise S.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Herzfeldt","sequence":"additional","affiliation":[{"name":"Department of Raw Material Production, Post Graduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Porto Alegre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eveline D.","family":"Stolz","sequence":"additional","affiliation":[{"name":"Department of Raw Material Production, Post Graduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Porto Alegre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.M.","family":"Fraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliezer","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stela M.K.","family":"Rates","sequence":"additional","affiliation":[{"name":"Department of Raw Material Production, Post Graduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Porto Alegre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230910","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0079-6123(08)00905-9","article-title":"Distribution of 5-HT and DA receptors in primate prefrontal cortex: implications for pathophysiology and treatment","volume":"172","author":"Almeida","year":"2008","journal-title":"Prog Brain Res"},{"key":"R2-20230910","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/FBP.0000000000000200","article-title":"LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model","volume":"27","author":"Antonio","year":"2016","journal-title":"Behav Pharmacol"},{"key":"R3-20230910","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/sj.npp.1301015","article-title":"Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5HT1A receptor activation and dopamine D2 receptor blockade","volume":"31","author":"Auclair","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R4-20230910","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.bbr.2009.05.015","article-title":"Differences among conventional, atypical and novel putative D2\/5-HT1A antipsychotics on catalepsyassociated behaviour in cynomolgus monkeys","volume":"203","author":"Auclair","year":"2009","journal-title":"Behav Brain Res"},{"key":"R6-20230910","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/026988110101500108","article-title":"The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?","volume":"15","author":"Bantick","year":"2001","journal-title":"J Psychopharmacol"},{"key":"R7-20230910","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.npp.1300940","article-title":"Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties","volume":"31","author":"Bardin","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R8-20230910","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1021\/cr200060g","article-title":"The methylation effect in medicinal chemistry","volume":"111","author":"Barreiro","year":"2011","journal-title":"Chem Rev"},{"key":"R13-20230910","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0014-2999(78)90251-0","article-title":"Climbing behavior induced by apomorphine in mice: a potential model for the detection of neuroleptic activity","volume":"50","author":"Costall","year":"1978","journal-title":"Eur J Pharmacol"},{"key":"R14-20230910","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/(SICI)1097-4547(20000115)59:2<202::AID-JNR6>3.0.CO;2-5","article-title":"Quantitative analysis of the dopamine D4 receptor in the mouse brain","volume":"59","author":"Defagot","year":"2000","journal-title":"J Neurosci Res"},{"key":"R15-20230910","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1523\/JNEUROSCI.2999-05.2005","article-title":"Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action","volume":"25","author":"Diaz-Mataix","year":"2005","journal-title":"J Neurosci"},{"key":"R16-20230910","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"New one-trial test for neurobiological studies of memory in rats. 1: behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav Brain Res"},{"key":"R17-20230910","first-page":"268","article-title":"Atypicality of atypical antipsychotics","volume":"7","author":"Farah","year":"2005","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"R18-20230910","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.pnpbp.2003.09.003","article-title":"Animal behavior models of the mechanisms underlying antipsychotic activity","volume":"27","author":"Geyer","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R19-20230910","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"R20-20230910","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1098\/rstb.1996.0129","article-title":"The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive","volume":"351","author":"Goldman-Rakic","year":"1996","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"R21-20230910","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejmech.2012.08.011","article-title":"Biotransformation of LASSBio-579 and pharmacological evaluation of p-hydroxylated metabolite a N-phenylpiperazine antipsychotic lead compound","volume":"62","author":"Gomes","year":"2013","journal-title":"Eur J Med Chem"},{"key":"R22-20230910","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbr.2007.06.012","article-title":"Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat","volume":"184","author":"Grayson","year":"2007","journal-title":"Behav Brain Res"},{"key":"R23-20230910","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.pnpbp.2004.08.003","article-title":"Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy","volume":"28","author":"Haleem","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R24-20230910","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/10550490050172209","article-title":"Stimulant psychosis: symptom profile and acute clinical course","volume":"9","author":"Harris","year":"2000","journal-title":"Am J Addict"},{"key":"R25-20230910","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","article-title":"5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release","volume":"76","author":"Ichikawa","year":"2001","journal-title":"J Neurochem"},{"key":"R26-20230910","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"Br J Pharmacol"},{"key":"R27-20230910","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R29-20230910","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1021\/jo00211a028","article-title":"Zinc-modified cyanoborohydride as a selective reducing agent","volume":"50","author":"Kim","year":"1985","journal-title":"J Org Chem"},{"key":"R31-20230910","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0893-133X(01)00243-3","article-title":"Effects of ketamine in normal and schizophrenic volunteers","volume":"25","author":"Lahti","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"R32-20230910","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbr.2009.11.037","article-title":"Dopamine D4-receptor modulation of cortical neuronal network activity and emotional processing: Implications for neuropsychiatric disorders","volume":"208","author":"Lauzon","year":"2010","journal-title":"Behav Brain Res"},{"key":"R33-20230910","first-page":"303","article-title":"Pharmacology of a human dopamine D4 receptor expressed in HEK293 cells","volume":"16","author":"Lawson","year":"1994","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"R34-20230910","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejphar.2007.09.016","article-title":"Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice","volume":"578","author":"Leite","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"R35-20230910","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/JCP.0b013e31827b97a6","article-title":"Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia","volume":"33","author":"Lerond","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"R36-20230910","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"R37-20230910","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R38-20230910","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0022-3565(24)29309-5","article-title":"Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation","volume":"299","author":"Liu","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"R39-20230910","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"R40-20230910","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/sj.bjp.0701465","article-title":"Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists","volume":"122","author":"Maemoto","year":"1997","journal-title":"Br J Pharmacol"},{"key":"R41-20230910","first-page":"823","article-title":"Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs","volume":"46","author":"Maina","year":"2005","journal-title":"J Nucl Med"},{"key":"R42-20230910","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s002130050501","article-title":"Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition","volume":"135","author":"Mansbach","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"R43-20230910","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00213-002-1240-x","article-title":"Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat","volume":"165","author":"Martin","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"R44-20230910","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/j.2051-5545.2009.tb00202.x","article-title":"Much ado about small differences","volume":"8","author":"McEvoy","year":"2009","journal-title":"World Psychiatry"},{"key":"R45-20230910","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotics drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu Rev Med"},{"key":"R46-20230910","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"R47-20230910","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1016\/S0968-0896(03)00487-5","article-title":"Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands","volume":"11","author":"Menegatti","year":"2003","journal-title":"Bioorg Med Chem"},{"key":"R48-20230910","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0022-3565(24)37732-8","article-title":"S-16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin 5-HT1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol","volume":"286","author":"Millan","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"R49-20230910","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"R50-20230910","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00176857","article-title":"Production of climbing behavior in mice requires both D1 and D2 receptor activation","volume":"94","author":"Moore","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"key":"R51-20230910","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00213-006-0572-3","article-title":"Acute and chronic effects of ketamine upon human memory: a review","volume":"188","author":"Morgan","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"R52-20230910","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/381245a0","article-title":"Localization of dopamine D4 receptors in GABAergic neurons of the primate brain","volume":"381","author":"Mrzljak","year":"1996","journal-title":"Nature"},{"key":"R53-20230910","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.bmc.2010.01.040","article-title":"Searching for multi-target antipsychotics: discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors","volume":"18","author":"Neves","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"R54-20230910","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bbr.2012.09.016","article-title":"New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia","volume":"237","author":"Neves","year":"2013","journal-title":"Behav Brain Res"},{"key":"R55-20230910","first-page":"8","article-title":"Antipsychotic medications: metabolic and cardiovascular risk","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R56-20230910","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives","volume":"11","author":"Newman-Tancredi","year":"2010","journal-title":"Curr Opin Invest Drugs"},{"key":"R57-20230910","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1017\/S1461145704005000","article-title":"Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia","volume":"8","author":"Newman-Tancredi","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"R58-20230910","first-page":"1202","article-title":"[3H]-rauwolscine binding to alpha 2-adrenoceptors in the mammalian kidney: apparent receptor heterogeneity between species","volume":"122","author":"Neylon","year":"1985","journal-title":"Br J Pharmacol"},{"key":"R59-20230910","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.vascn.2014.03.002","article-title":"Functional binding assays for estimation of the intrinsic efficacy of ligands at the 5-HT1A receptor: application for screening drug candidates","volume":"70","author":"No\u00ebl","year":"2014","journal-title":"J Pharmacol Toxicol Methods"},{"key":"R61-20230910","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1126\/science.2660263","article-title":"Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs","volume":"244","author":"Olney","year":"1989","journal-title":"Science"},{"key":"R62-20230910","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/00003495-199651060-00001","article-title":"Adverse effects of antipsychotic agents: do newer agents offer advantages?","volume":"51","author":"Owens","year":"1996","journal-title":"Drugs"},{"key":"R63-20230910","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejmech.2013.05.027","article-title":"Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579","volume":"66","author":"Pompeu","year":"2013","journal-title":"Eur J Med Chem"},{"key":"R64-20230910","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1124\/jpet.110.166710","article-title":"Behavioral indices in antipsychotic drug discovery","volume":"333","author":"Porsolt","year":"2010","journal-title":"J Pharm Exp Ther"},{"key":"R65-20230910","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0014-2999(98)00536-6","article-title":"The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties","volume":"356","author":"Prinssen","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"R66-20230910","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjp.0703139","article-title":"Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex","volume":"129","author":"Sakaue","year":"2000","journal-title":"Br J Pharmacol"},{"key":"R68-20230910","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1124\/jpet.109.151118","article-title":"Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one","volume":"330","author":"Satow","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"R69-20230910","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3371\/CSRP.4.1.5","article-title":"Dopamine D2 receptors as treatment targets in schizophrenia","volume":"1","author":"Seeman","year":"2010","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"R70-20230910","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"A novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R71-20230910","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.pnpbp.2010.04.005","article-title":"Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders","volume":"34","author":"Shimizu","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R72-20230910","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2571","article-title":"Schizophrenia therapy: beyond atypical antipsychotics","volume":"7","author":"Snyder","year":"2008","journal-title":"Drug Discov"},{"key":"R73-20230910","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0269881110387840","article-title":"PD168077, a D(4) receptor agonist, reverses object recognition deficits in rats: potential role for D(4) receptor mechanisms in improving cognitive dysfunction in schizophrenia","volume":"25","author":"Sood","year":"2011","journal-title":"J Psychopharmacol"},{"key":"R74-20230910","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/npp.2008.74","article-title":"Decreased dopamine D4 receptor expression increases extracellular glutamate and alters its regulation in mouse striatum","volume":"34","author":"Thomas","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"R75-20230910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnbeh.2014.00291","article-title":"Tandospirone, a 5HT1A partial agonist, ameliorates aberrante lactate production in the pre-frontal cortex of rats exposed to blockade of N-methyl-d-aspartate receptors; toward the therapeutics of cognitive impairment of schizophrenia","volume":"8","author":"Uehara","year":"2014","journal-title":"Front Behav Neurosci"},{"key":"R76-20230910","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/350610a0","article-title":"Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine","volume":"350","author":"Van Tol","year":"1991","journal-title":"Nature"},{"key":"R77-20230910","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1017\/S1461145706006638","article-title":"Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive \u03b12 adrenoceptor blockade: experimental evidence","volume":"10","author":"Wadenberg","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"R78-20230910","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.pnpbp.2003.09.005","article-title":"The dopamine D4 receptors and mechanism of antipsychotic atypicality","volume":"27","author":"Wong","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R79-20230910","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pbb.2014.06.008","article-title":"Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonina 5-HT1A receptors","volume":"124","author":"Yoshimi","year":"2014","journal-title":"Pharmacol Biochem Behav"},{"key":"R80-20230910","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbr.2011.03.054","article-title":"The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: separating response inhibition from premature responding","volume":"222","author":"Young","year":"2011","journal-title":"Behav Brain Res"},{"key":"R81-20230910","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1523\/JNEUROSCI.5050-08.2009","article-title":"Dopamine D4 receptors regulate AMPA receptor trafficking and glutamatergic transmission in GABAergic interneurons of prefrontal cortex","volume":"29","author":"Yuen","year":"2009","journal-title":"J Neurosci"},{"key":"R82-20230910","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00213-002-1018-1","article-title":"Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions","volume":"161","author":"Zhang","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"R83-20230910","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/sj.npp.1300491","article-title":"Regulation of working memory by dopamine D4 receptor in rats","volume":"29","author":"Zhang","year":"2004","journal-title":"Neuropsychopharmacology"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008877-201702000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T12:16:32Z","timestamp":1749644192000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008877-201702000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000267","relation":{},"ISSN":["0955-8810"],"issn-type":[{"type":"print","value":"0955-8810"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}